Accessibility Menu
Profusa logo

Profusa(NASDAQ) PFSA

Current Price$1.70
Market Cap$932.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-100%
1 Month-51%
Profusa last closing stock price
MetricPriceDate
Last closeUSD 1.762026-07-23
Profusa stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.38%USD 1.862026-07-16
1 month-51.11%USD 3.602026-06-23
3 month-87.8%USD 14.432026-04-24
Year to date-99.1%USD 196.502025-12-31
1 year-99.88%USD 1,500.002025-07-23
3 year-99.99%USD 19,706.252023-07-21
Since inception-99.99%USD 18,206.302022-01-24

Profusa Financials at a Glance

Market Cap

$932.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$42.41M

EPS (TTM)

-$4,495.51

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.48 (Low)

Price

$1.70

Volume

25,948

Open

$1.76

Previous Close

$1.71

Daily Range

$1.60 - $1.80

52-Week Range

$1.60 - $4,162.50

Estimated Earnings Date

Mar 25, 2026

PFSA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Profusa

Profusa creates biosensors that track body chemistry for people with chronic diseases. Its main product helps monitor oxygen in tissue, supporting better health management. The company aims to make health tracking less invasive and more continuous.

Gadgets That Listen to Your Body

  • Tissue-integrating biosensors: Devices placed under the skin to monitor body chemistry in real time. (0% of revenue; no sales yet)
  • Lumee Oxygen Platform: Measures oxygen levels in tissue for patients with chronic conditions. (0% of revenue; no sales yet)
  • AI-powered health insights: Software interprets biosensor data to help patients and doctors make decisions. (0% of revenue; no sales yet)

Plot Twists and Pivots

  • Completed a business combination (merger) in July 2025, forming the current public company.
  • Entered a Securities Purchase Agreement in July 2025, allowing up to $100 million in new stock sales.
  • Issued a $10 million principal amount convertible note in July 2025, with more funding possible.
  • Delisted from NASDAQ in December 2024; now trades on the OTC Market.

Why Profusa Is a Bit Different

Profusa’s biosensors aim to reduce the need for frequent blood tests by providing continuous data. The company uses artificial intelligence to turn sensor readings into practical health advice. Its focus is on digital health tools for chronic disease management, a field with ongoing demand.

Five Things You Need to Know

  • No revenue reported for Q2 2025 or Q2 2024 (0% change).
  • Net loss was $8 million in Q2 2025, down 1962.2% from Q2 2024.
  • Operating loss was $967,084 in Q2 2025, down 282.1% from Q2 2024.
  • Working capital deficit was $15,492,554 as of June 30, 2025.
  • Only 2 full-time employees as of the latest report.

Bottom Line

Profusa is developing biosensor technology but has not yet generated revenue. The company faces financial challenges as it works toward commercializing its products.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

2

CEO

Ben Hwang, PhD

Website

profusa.com

Headquarters

Berkeley, CA 94710, US

PFSA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

154.23%

Return on Capital

N/A

Return on Assets

-4920.17%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$932.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

530.00K

Volume

25.95K

Avg. Volume

180.03K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$30.25M

EBITDA

-$40.69M

Operating Cash Flow

-$18.46M

Capital Expenditure

-$5.00K

Free Cash Flow

-$18.47M

Cash & ST Invst.

$375.00K

Total Debt

$12.54M

Profusa Performance Analysis

Profusa annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 100,000N/A
20252025-12-31USD 0N/A
Profusa sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Profusa annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 556.072285.9%
20232023-12-31USD 216.56-61.1%
20242024-12-31USD -8,928.36N/A
20252025-12-31USD -2,675.19-70.0%
Profusa sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3098.5%
Q32025-09-3055.7%
Q42025-12-3186.7%
Q12026-03-3170.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$932.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$466.40K

N/A

Employees

2

N/A

Net Income

-$3.46M

-27.2%

EBITDA

-$3.38M

-127.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$375.00K

+1873.7%

Total Debt

$12.54M

-75.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$12.54M

-75.0%

Return on Assets

-49.20%

N/A

Return on Invested Capital

1.07%

N/A

Free Cash Flow

-$2.58M

-380.6%

Operating Cash Flow

-$2.58M

-379.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HCWBHCW Biologics Inc.
$2.50-13.19%
SBFMSunshine Biopharma, Inc.
$1.66-2.92%
GBSGBS Inc.
$0.47-1.58%
ACXPAcurx Pharmaceuticals, Inc.
$1.42-2.07%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%

Questions About PFSA

What is the current price of Profusa?

Profusa is trading at $1.71 per share.

What is the 52-week range for Profusa?

Over the past 52 weeks, Profusa has traded between $1.60 and $4,162.50.

How much debt does Profusa have?

As of the most recent reporting period, Profusa reported total debt of $12.54M.

How much cash does Profusa have on hand?

Profusa reported $375.00K in cash and cash equivalents in its most recent financial results.

What is Profusa’s dividend yield?

Profusa does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services